Evonik Develops Animal-Free, Fermentation-Based Collagen Platform

Evonik has developed an advanced collagen platform that is made via fermentation-based processes and devoid of animal- or human-derived materials. According to the company, the recombinant technology will provide pharmaceutical, medical, cell culture and tissue engineering markets with a highly soluble, ultra-pure form of collagen that is safe, sustainable and commercially scalable.

Evonik's collagen platform features a triple helix structure and other biological properties that mimic many of the attributes of natural collagen so it can reliably interact with cells and tissues and be readily absorbed or remodeled by the body.

Animal-sourced collagen, currently the main source of collagen for use in life sciences, can be associated with batch-to-batch variability, potential transmission of diseases or pathogens, adverse immunogenic or allergic reactions, and non-sustainable sourcing methods. Evonik's collagen is produced under controlled conditions via a fermentation-based process.

Evonik will use its established fermentation process technologies and global manufacturing network to commercialize the collagen platform for worldwide use. The company's application, formulation and manufacturing competencies will also be used to help customers develop and commercialize their own biofabricated products.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.